Search

To investigate the polymorphism of T cell receptor β chain variable region (TCRV β) in peripheral blood of clinically isoiated syndrome (CIS) patients. To preliminarily predict the specific TCRV β fragment of CIS and its diagnostic value for CIS. Methods Hospitalized patients of Beijing Xuanwu Hospital from September 2012 to March 2014, were divided into 2 groups including CIS group (experimental pateints, n = 30) and normal control group (healthy volunteers, n = 30). The routine immune indexes and expression of TCRVβ subfamilies were detected by flow cytometry. CELL Quest Pro 5.1 software was used to analyze 24 subfamilies of TCRVβ. Calculated the statistic of amplification rate, amplification number and amplification fraction of the total 24 subfamilies of TCRVβ. Results Compared to the normal control group, the quantitative expression of CD4+ TCRVβ2, 4, 5.2, 5.3, 7.1, 8, 14, 17, 20, 21.3 and CD8+TCRVβ4, 14 were significantly expanded in CIS group, CD4+TCRVβ11 and CD8+TCRVβ9, 11 were significantly reduced in CIS group (P < 0.05 or P < 0.01). The amplification rate of CD4+TCRVβ2 (P = 0.002) and CD8+TCRVβ14 (P = 0.010) in CIS group were higher than those in normal control group, but there was no significant difference in the other subfamilies. There was no statistical difference in the expansion rate of the TCRVβ between CIS group and normal control group. The amplification number (P = 0.001) and amplification fraction (P = 0.006) of the TCRVβ in CIS group were significantly higher than the normal control group. Receiver operating characteristic curve (ROC) analysis indicated that the area under the curve (AUC) of CD4+TCRVβ4 in the diagnosis of CIS was 0.719 (95%CI: 0.592-0.851, P = 0.003). The sensitivity was 83.33%, the specificity was 56.67%. The AUC of CD4+TCRVβ14 in the diagnosis of CIS was 0.713 (95%CI: 0.581-0.845, P = 0.005). The sensitivity was 70%, the specificity was 56.23%. The AUC of CD8+TCRVβ4 in the diagnosis of CIS was 0.727 (95%CI: 0.600-0.854, P = 0.002). The sensitivity was 93.33%, the specificity was 50%. The three fragments have medium diagnostic value for CIS. Conclusions Although the expression levels of CD4+TCRV β4, CD4+TCRV β14 and CD8+TCRV β4 in peripheral blood are increased in CIS group, their diagnostic value is limited. [ABSTRACT FROM AUTHOR]

COVID-19 has brought the world to a standstill with a wave of destruction in country after country with tremendous loss of lives and livelihood in advanced to developing nations. Whole world is staring at the prospect of repeated lockdowns with another wave of COVID-19 predicted to hit the world in September of 2020. The second wave is assumed to be even more destructive with severe impact across much of the world. The only way to defeat this pandemic is to quickly develop a safe and effective vaccine against this raging menace and initiate a global vaccination drive. Our study is an attempt to deploy various computational methods to identify B-cell and T-cell epitopes from the spike surface glycoprotein of SARS-COV-2 which have the novel potential for vaccine development against COVID-19. For this we have taken 8 unique strains with one each from India, China, France, USA, Italy, Australia, Iran and Pakistan. The strain data was extracted from NCBI Database. By analyzing the immune parameters like surface accessibility, antigenicity, variability, conservancy, flexibility, hydrophilicity, allergenicity and toxicity of the conserved sequences of spike glycoprotein using various databases and bioinformatics tools, we identified two potential novel linear (SGTNGTKRFDN and ASVYAWNRK) and one structural B-cell epitope as well as two T-cell epitopes (RLFRKSNLK and IPTNFTISV) which can be used as epitope-based peptide vaccines. Docking simulation assay revealed that above T-cell epitopes have minimum free binding energy and showed strong hydrogen bond interaction which strengthened its potential as being a T-cell epitope for the epitope-based novel vaccine against SARS-CoV-2. This study allows us to claim that B-cell and T-cell epitopes mentioned above provide potential pathways for developing an exploratory vaccine against spike surface glycoprotein of SARS-CoV-2 with high confidence for the identified strains. We will need to confirm our findings with biological assays., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Ltd. All rights reserved.)